{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T10:07:13Z","timestamp":1770890833117,"version":"3.50.1"},"reference-count":17,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1016\/j.ygyno.2016.12.011","type":"journal-article","created":{"date-parts":[[2016,12,17]],"date-time":"2016-12-17T20:47:22Z","timestamp":1482007642000},"page":"256-259","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":37,"title":["Feasibility and outcome of interval debulking surgery (IDS) after carboplatin-paclitaxel-bevacizumab (CPB): A subgroup analysis of the MITO-16A-MaNGO OV2A phase 4 trial"],"prefix":"10.1016","volume":"144","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5360-1895","authenticated-orcid":false,"given":"Gennaro","family":"Daniele","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Domenica","family":"Lorusso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Scambia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabrina C.","family":"Cecere","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Ornella","family":"Nicoletto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enrico","family":"Breda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicoletta","family":"Colombo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grazia","family":"Artioli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucia","family":"Cannella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Lo Re","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Raspagliesi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppa","family":"Maltese","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vanda","family":"Salutari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriella","family":"Ferrandina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefano","family":"Greggi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandra","family":"Baldoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alice","family":"Bergamini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Carmela","family":"Piccirillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Germana","family":"Tognon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irene","family":"Floriani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simona","family":"Signoriello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Perrone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandro","family":"Pignata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2016.12.011_bb0005","article-title":"GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]","author":"Ferlay","year":"2013","journal-title":"In. Lyon, France: International Agency for Research on Cancer"},{"key":"10.1016\/j.ygyno.2016.12.011_bb0010","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1517\/14712598.2014.873401","article-title":"New biological treatments for gynecological tumors: focus on angiogenesis","volume":"14","author":"Daniele","year":"2014","journal-title":"Expert. Opin. Biol. Ther."},{"key":"10.1016\/j.ygyno.2016.12.011_bb0015","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1056\/NEJMoa1104390","article-title":"Incorporation of bevacizumab in the primary treatment of ovarian cancer","volume":"365","author":"Burger","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2016.12.011_bb0020","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1056\/NEJMoa1103799","volume":"365","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2016.12.011_bb0025","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1200\/JCO.2012.42.0505","article-title":"OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer","volume":"30","author":"Aghajanian","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2016.12.011_bb0030","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2013.51.4489","article-title":"Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial","author":"Pujade-Lauraine","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2016.12.011_bb0035","doi-asserted-by":"crossref","first-page":"abstr 5523","DOI":"10.1200\/JCO.2016.34.15_suppl.5523","article-title":"Bevacizumab after bevacizumab in platinum-sensitive recurrent ovarian cancer: a subgroup analysis of GOG0213. In: ASCO annual meeting. Chicago","author":"Coleman","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2016.12.011_bb0040","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/nrclinonc.2015.224","article-title":"Can advanced-stage ovarian cancer be cured?","volume":"13","author":"Narod","year":"2016","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2016.12.011_bb0045","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0140-6736(14)62223-6","article-title":"Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial","volume":"386","author":"Kehoe","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.ygyno.2016.12.011_bb0050","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1056\/NEJMoa0908806","article-title":"Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer","volume":"363","author":"Vergote","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2016.12.011_bb0055","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.1053\/j.seminoncol.2006.08.001","article-title":"Bevacizumab in the treatment of metastatic colorectal cancer: safety profile and management of adverse events","volume":"33","author":"Hurwitz","year":"2006","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.ygyno.2016.12.011_bb0060","doi-asserted-by":"crossref","first-page":"S553","DOI":"10.1016\/S0959-8049(16)31532-5","article-title":"2766 Safety of bevacizumab-containing neoadjuvant therapy followed by interval debulking surgery in advanced ovarian cancer: data from the ANTHALYA trial","volume":"51","author":"Selle","year":"2016","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ygyno.2016.12.011_bb0065","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1245\/s10434-011-2134-0","article-title":"Feasibility of surgery after systemic treatment with the humanized recombinant antibody bevacizumab in heavily pretreated patients with advanced epithelial ovarian cancer","volume":"19","author":"Sehouli","year":"2012","journal-title":"Ann. Surg. Oncol."},{"key":"10.1016\/j.ygyno.2016.12.011_bb0070","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1097\/IGC.0000000000000107","article-title":"Feasibility of interval cytoreduction following neoadjuvant chemotherapy with carboplatin, weekly paclitaxel, and bevacizumab for advanced ovarian cancer\u2014a phase 1 study","volume":"24","author":"Salani","year":"2014","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"Suppl. 3","key":"10.1016\/j.ygyno.2016.12.011_bb0075","doi-asserted-by":"crossref","first-page":"S952","DOI":"10.1245\/s10434-015-4651-8","article-title":"Neoadjuvant chemotherapy followed by maintenance therapy with or without bevacizumab in unresectable high-grade serous ovarian cancer: a case-control study","volume":"22","author":"Petrillo","year":"2015","journal-title":"Ann. Surg. Oncol."},{"key":"10.1016\/j.ygyno.2016.12.011_bb0080","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1097\/IGC.0b013e31829dc923","article-title":"Morbidity of surgery after neoadjuvant chemotherapy including bevacizumab for advanced ovarian cancer","volume":"23","author":"Chereau","year":"2013","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2016.12.011_bb0085","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.ygyno.2010.01.011","article-title":"Which factors predict bowel complications in patients with recurrent epithelial ovarian cancer being treated with bevacizumab?","volume":"118","author":"Richardson","year":"2010","journal-title":"Gynecol. Oncol."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825816316699?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825816316699?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,16]],"date-time":"2019-09-16T13:22:05Z","timestamp":1568640125000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825816316699"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2]]},"references-count":17,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,2]]}},"alternative-id":["S0090825816316699"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2016.12.011","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2017,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Feasibility and outcome of interval debulking surgery (IDS) after carboplatin-paclitaxel-bevacizumab (CPB): A subgroup analysis of the MITO-16A-MaNGO OV2A phase 4 trial","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2016.12.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}